Relapse and side effects of steroid therapy beyond 3 years in autoimmune pancreatitis: A multicenter retrospective study

• Published in: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2024-03, Vol.24 (2), p.223-231
• Main Authors: Tsujimae, Masahiro, Masuda, Atsuhiro, Takagi, Megumi, Kato, Takao, Nakano, Ryota, Fujita, Koichi, Hirata, Yuichi, Kakuyama, Saori, Furumatsu, Keisuke, Nakagawa, Takashi, Ogisu, Kyohei, Fujigaki, Seiji, Iemoto, Takao, Ezaki, Takeshi, Yagi, Yosuke, Ikegawa, Takuya, Yamanaka, Kodai, Sato, Yu, Juri, Noriko, Kobayashi, Takashi, Sakai, Arata, Shiomi, Hideyuki, Sanuki, Tsuyoshi, Arisaka, Yoshifumi, Okabe, Yoshihiro, Kodama, Yuzo
• Format: Article
• Language: English
• Subjects: Autoimmune pancreatitis; Macrovascular complications; Maintenance therapy; Malignancy; Prognosis
• ISSN: 1424-3903; 1424-3911
• DOI: 10.1016/j.pan.2024.01.006

The impact of extended steroid administration on patients with autoimmune pancreatitis after a 3-year maintenance period remains poorly understood. This study analyzed the advantage and disadvantage of continuing steroid therapy beyond 3 years. In this retrospective multicenter study across 17 institutions, patients who successfully completed 3 years of maintenance therapy without experiencing relapse were categorized into two groups: the maintenance therapy discontinuation group, who discontinued steroid therapy after the initial 3-year period, and maintenance therapy continuation group, who continued steroid therapy beyond 3 years. The cumulative relapse rate after 3 years of maintenance therapy was the primary outcome. Relapse predictors were compared using the Gray test for cumulative relapse incidence by specific factor. Of 211 patients, 105 experienced no relapse during the 3-year maintenance therapy and were divided into two groups: 69 in the maintenance therapy discontinuation group and 36 in the maintenance therapy continuation group. The relapse rate was lower in the maintenance therapy continuation group than in the maintenance therapy discontinuation group (P = 0.035). Predictors of relapse after 3 years included cessation of maintenance therapy (hazard ratio [HR] = 3.76; 95 % confidence interval [CI] = 1.07–13.3, P = 0.040) and renal involvement (HR = 2.88; 95 % CI = 1.04–7.99, P = 0.042). The maintenance therapy continuation group showed a significantly higher prevalence of macrovascular complications, compared with the maintenance therapy discontinuation group (P = 0.005). Cessation of steroid maintenance therapy and renal involvement were predictors of relapse after 3 years of maintenance therapy. However, the long-term use of steroids may increase the risk of macrovascular complications.